Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

About Transgene:

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is avai
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend of twelve cents per outstanding share, ... at the close of business on June 12, 2015. ... in 1906, Kewaunee Scientific Corporation is a recognized global ... healthcare, and technical furniture products. Products include steel, wood, ...
(Date:6/2/2015)... REPORT HIGHLIGHTS The global market for ... This market is expected to increase from more than $4.1 ... compound annual growth rate (CAGR) of 13.6% over the five-year ... An in-depth analysis of the global markets and ... from 2013, estimates for 2014, and projections of compounds annual ...
(Date:6/2/2015)... , June 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Drug ... Markets and Companies" to their offering. ... system (CNS) is a challenge in the treatment ... into the CNS or administered systematically (e.g., by ...
Breaking Medicine Technology:Global Markets and Technologies for Medical Lasers 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3
... Genmab A/S (OMX:,GEN) announced today a Phase ... of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA),patients, stable ... which,will consist of two parts and include approximately ... addition of a subcutaneous method of administrating ofatumumab ...
... and benefits of early treatment ... with liraglutide versus glimepiride, SAN FRANCISCO, June ... the American Diabetes Association (ADA),demonstrated that once-daily liraglutide when taken ... with type 2 diabetes, as compared to glimepiride, a widely ...
Cached Medicine Technology:Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study 2Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study 3Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 2Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 3Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 4
(Date:6/3/2015)... Veatch Consulting Services is excited to announce their ... business in April 2006, they have made it a ... Each and every year they have worked diligently in ... say that they are off to a great start ... this year is the Customer Review site veatchconsultingreviews.weebly.com. At ...
(Date:6/3/2015)... Israel (PRWEB) June 03, 2015 ... emergency mass-notification, multi-channel solutions, reported of its "behind-the-scenes" ... the past few months. Since March this year, ... has been inflicting the South-American country, putting millions ... ash and gas into the atmosphere. "evigilo's technology, ...
(Date:6/2/2015)... (PRWEB) June 03, 2015 BALTIMORE, Md. ... to write a book about wellness after being diagnosed ... she believes that through lifestyle changes which enhance health, ... In “ A Wellspring for Wellness ,” she ... diseases. , This book provides an overview of ...
(Date:6/2/2015)... The organic cotton market is again growing according ... conducted by Textile Exchange, an international nonprofit organization committed ... today, encompasses extensive data about organic cotton from seed ... takes the opportunity to celebrate those who are building ... last several years have been complicated for the organic ...
(Date:6/2/2015)... Kan. (PRWEB) June 02, 2015 Concorde ... Bell as President and COO. Bell will manage day-to-day ... , “I’m looking forward to the opportunity to help ... students,” Bell said. “I joined Concorde in part due ... Institute that highlighted Concorde colleges in Memphis and Portland.” ...
Breaking Medicine News(10 mins):Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:Thousands of Lives Saved, Millions Protected in Chile 2Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 4Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 5Health News:Concorde Career Colleges Announces New President and COO 2
... poultry made its way to the food chain via the ... strain// of bird flu in early February this year. ... almost 850 tons of turkey had to pass through the ... the interim period between outbreak of the avian influenza and ...
... Haikerwal, today urged more Australians to donate blood and donate ... ,Dr Haikerwal said the AMA strongly supports the ... designed to raise the number of Australian blood donors and ... year. ,“Blood donors save lives,” Dr Haikerwal ...
... are varied reactions to the U.S panel hearing ... , The Senate Health, Education, Labor and ... Food and Drug Administration legal authority to approve alternative ... Yet it has drawn both brickbats and ...
... article published in the prestigious international journal 'The Lancet' by ... Darwin// has revealed a breakthrough in the battle to treat ... the worlds population. ,There are two major strains ... attention focuses on the more virulent P. falciparum, vivax malaria ...
... in a duck farm in Chonan, in central South Korea. ... bird flu on Thursday//. The cause was identified as "highly ... bird flu outbreak since November reported in South Korea. H5N1 ... Korea. ,The culling of over 55,000 poultry will ...
... According to statistics over one lac people Indians are diagnosed ... die as they do not get timely treatment. ... Check-up package in connection with World Kidney Day-2007. The camp ... and urine analysis for random glucose and creatinine. ...
Cached Medicine News:Health News:Generic Biologics – U.S Panel Hearing Draws Mixed Response 2Health News:Researchers Discover Breakthrough in Malaria Treatment 2
... manual autoclaves set the standard for steam ... to compliment any healthcare and laboratory facility. ... of your sterilization needs. Time tested reliability ... product. The Tuttnauer M Series is also ...
Subjective refraction unit, computer controlled and programmable. Two versions: with and without prisms....
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
Non-sterile oncoseed seeds consists of a welded titanium capsule containing....
Medicine Products: